Elanco Animal Health Incorporated (NYSE:ELAN) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analyst consensus is “Moderate Buy”: Eight of 12 analysts rate Elanco a buy, one rates it a strong buy, and the average 12-month price target is $29.70 versus a recent price of $22.41.
• Quarterly results exceeded expectations: Elanco reported $0.34 in adjusted EPS against a $0.27 estimate and revenue of $1.37 billion, up 10.2% year over year.
• Insider and institutional interest remains notable: Company insiders purchased 63,198 shares worth $1.47 million over the past 90 days, while institutional investors and hedge funds own 97.48% of the stock.

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twelve research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $29.70.

Several research analysts have recently issued reports on the company. Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, September 4th. UBS Group upped their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, August 6th. KeyCorp increased their target price on Elanco Animal Health from $29.00 to $30.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. TD Cowen raised their target price on Elanco Animal Health from $31.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, June 18th. Finally, Morgan Stanley boosted their target price on Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 22nd.

Elanco Animal Health Trading Up 0.3%

Shares of NYSE ELAN opened at $22.41 on Friday. The company's 50 day simple moving average is $24.04 and its 200 day simple moving average is $23.74. Elanco Animal Health has a fifty-two week low of $18.93 and a fifty-two week high of $27.98. The firm has a market capitalization of $11.20 billion, a P/E ratio of -54.65, a P/E/G ratio of 1.59 and a beta of 1.68. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the firm earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, analysts predict that Elanco Animal Health will post 1.13 EPS for the current year.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Michael Harrington acquired 5,000 shares of Elanco Animal Health stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average price of $21.82 per share, with a total value of $109,100.00. Following the purchase, the director directly owned 131,451 shares of the company's stock, valued at $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert Vanhimbergen acquired 4,200 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average price of $23.08 per share, with a total value of $96,936.00. Following the acquisition, the chief financial officer owned 137,516 shares of the company's stock, valued at approximately $3,173,869.28. This trade represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 63,198 shares of company stock worth $1,473,109 over the last ninety days. 1.14% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. Anchor Investment Management LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth $29,000. Integrated Wealth Concepts LLC bought a new position in Elanco Animal Health during the second quarter worth about $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Elanco Animal Health in the second quarter valued at about $38,000. Root Financial Partners LLC grew its stake in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after acquiring an additional 592 shares during the period. Finally, Bessemer Group Inc. increased its holdings in shares of Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock worth $50,000 after acquiring an additional 525 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated NYSE: ELAN is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company's products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.